{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T12:40:47Z","timestamp":1760964047819,"version":"build-2065373602"},"reference-count":38,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100009328","name":"PBC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009328","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","surgonc.theclinics.com","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Surgical Oncology Clinics of North America"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.soc.2019.08.007","type":"journal-article","created":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T17:06:46Z","timestamp":1574183206000},"page":"87-103","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Individualizing Care"],"prefix":"10.1016","volume":"29","author":[{"given":"Laura","family":"Cristoferi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Nardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pietro","family":"Invernizzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George","family":"Mells","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Carbone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.soc.2019.08.007_bib1","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1056\/NEJMp1500523","article-title":"A\u00a0new initiative on precision medicine","volume":"372","author":"Collins","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.soc.2019.08.007_bib2","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jhep.2017.03.022","article-title":"EASL clinical practice guidelines: the diagnosis and management of patients with primary biliary cholangitis","volume":"67","author":"Hirschfield","year":"2017","journal-title":"J\u00a0Hepatol"},{"issue":"1","key":"10.1016\/j.soc.2019.08.007_bib3","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1002\/hep.21229","article-title":"Development of autoimmune hepatitis in patients with typical primary biliary cirrhosis","volume":"44","author":"Poupon","year":"2006","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.soc.2019.08.007_bib4","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1002\/hep.510280203","article-title":"Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy","volume":"28","author":"Chazouill\u00e8res","year":"1998","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.soc.2019.08.007_bib5","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.jhep.2015.06.030","article-title":"EASL clinical practice guidelines: autoimmune hepatitis","volume":"63","year":"2015","journal-title":"J\u00a0Hepatol"},{"issue":"1","key":"10.1016\/j.soc.2019.08.007_bib6","first-page":"S364","article-title":"Autoimmune hepatitis patients with poor treatment response have a distinct liver transcriptome: implications for personalised therapy","volume":"66","author":"Millar","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.soc.2019.08.007_bib7","doi-asserted-by":"crossref","first-page":"450","DOI":"10.3389\/fneur.2017.00450","article-title":"Current and emerging technologies for probing molecular signatures of traumatic brain injury","volume":"8","author":"Ercole","year":"2017","journal-title":"Front Neurol"},{"issue":"2","key":"10.1016\/j.soc.2019.08.007_bib8","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1136\/gut.49.2.276","article-title":"Jaundice in non-cirrhotic primary biliary cirrhosis: the premature ductopenic variant","volume":"49","author":"Vleggaar","year":"2001","journal-title":"Gut"},{"issue":"6","key":"10.1016\/j.soc.2019.08.007_bib9","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.clinre.2013.04.005","article-title":"Diagnostic and clinical significance of anti-centromere antibodies in primary biliary cirrhosis","volume":"37","author":"Liberal","year":"2013","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"8","key":"10.1016\/j.soc.2019.08.007_bib10","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1111\/hepr.12423","article-title":"Autoantibody status and histological variables influence biochemical response to treatment and long-term outcomes in Japanese patients with primary biliary cirrhosis","volume":"45","author":"Nakamura","year":"2015","journal-title":"Hepatol Res"},{"issue":"1","key":"10.1016\/j.soc.2019.08.007_bib11","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1002\/hep.21472","article-title":"Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis","volume":"45","author":"Nakamura","year":"2007","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.soc.2019.08.007_bib12","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/S0168-8278(87)80035-1","article-title":"Portal hypertension in primary biliary cirrhosis","volume":"5","author":"Navasa","year":"1987","journal-title":"J\u00a0Hepatol"},{"issue":"10","key":"10.1016\/j.soc.2019.08.007_bib13","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1136\/gut.12.10.830","article-title":"Portal hypertension in primary biliary cirrhosis","volume":"12","author":"Kew","year":"1971","journal-title":"Gut"},{"issue":"3","key":"10.1016\/j.soc.2019.08.007_bib14","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1002\/hep.22428","article-title":"Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis","volume":"48","author":"Corpechot","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.soc.2019.08.007_bib15","doi-asserted-by":"crossref","first-page":"S805","DOI":"10.1016\/S0168-8278(15)31394-5","article-title":"P1198: histological stage is relevant for risk-stratification in primary biliary cirrhosis","volume":"62","author":"Carbone","year":"2015","journal-title":"J\u00a0Hepatol"},{"issue":"7","key":"10.1016\/j.soc.2019.08.007_bib16","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1136\/jcp.49.7.556","article-title":"Accuracy of staging in primary biliary cirrhosis","volume":"49","author":"Garrido","year":"1996","journal-title":"J\u00a0Clin Pathol"},{"issue":"2","key":"10.1016\/j.soc.2019.08.007_bib17","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/BF00432479","article-title":"Staging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis)","volume":"379","author":"Ludwig","year":"1978","journal-title":"Virchows Arch A Pathol Anat Histol"},{"issue":"3","key":"10.1016\/j.soc.2019.08.007_bib18","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/j.1440-1827.2009.02500.x","article-title":"Application of a new histological staging and grading system for primary biliary cirrhosis to liver biopsy specimens: interobserver agreement","volume":"60","author":"Nakanuma","year":"2010","journal-title":"Pathol Int"},{"key":"10.1016\/j.soc.2019.08.007_bib19","first-page":"233","article-title":"Histopathology of cholestasis","volume":"79","author":"Desmet","year":"1995","journal-title":"Verh Dtsch Ges Pathol"},{"issue":"3","key":"10.1016\/j.soc.2019.08.007_bib20","first-page":"715","article-title":"The significance of variations in the distribution of copper in liver disease","volume":"99","author":"Goldfischer","year":"1980","journal-title":"Am J Pathol"},{"issue":"10","key":"10.1016\/j.soc.2019.08.007_bib21","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1038\/ajg.2010.216","article-title":"Baseline ductopenia and treatment response predict long-term histological progression in primary biliary cirrhosis","volume":"105","author":"Kumagi","year":"2010","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"10.1016\/j.soc.2019.08.007_bib22","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1002\/hep.25599","article-title":"Noninvasive elastography-based assessment of liver fibrosis progression and prognosis in primary biliary cirrhosis","volume":"56","author":"Corpechot","year":"2012","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.soc.2019.08.007_bib23","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/j.jhep.2014.01.029","article-title":"Optimising risk stratification in primary biliary cirrhosis: AST\/platelet ratio index predicts outcome independent of ursodeoxycholic acid response","volume":"60","author":"Trivedi","year":"2014","journal-title":"J\u00a0Hepatol"},{"issue":"5","key":"10.1016\/j.soc.2019.08.007_bib24","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1002\/hep.22517","article-title":"Prediction of clinical outcomes in primary biliary cirrhosis by serum enhanced liver fibrosis assay","volume":"48","author":"Mayo","year":"2008","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.soc.2019.08.007_bib25","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.jhep.2013.03.016","article-title":"The Enhanced Liver Fibrosis (ELF) score: normal values, influence factors and proposed cut-off values","volume":"59","author":"Lichtinghagen","year":"2013","journal-title":"J\u00a0Hepatol"},{"issue":"8537","key":"10.1016\/j.soc.2019.08.007_bib26","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/S0140-6736(87)91610-2","article-title":"Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis?","volume":"329","author":"Poupon","year":"1987","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.soc.2019.08.007_bib27","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1053\/j.gastro.2012.12.005","article-title":"Sex and age are determinants of the clinical phenotype of primary biliary cirrhosis and response to ursodeoxycholic acid","volume":"144","author":"Carbone","year":"2013","journal-title":"Gastroenterology"},{"issue":"7","key":"10.1016\/j.soc.2019.08.007_bib28","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1053\/j.gastro.2015.07.061","article-title":"Development and validation of a scoring system to predict outcomes of patients with primary biliary cirrhosis receiving ursodeoxycholic acid therapy","volume":"149","author":"Lammers","year":"2015","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.soc.2019.08.007_bib29","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.jhep.2010.05.026","article-title":"The independent effects of fatigue and UDCA therapy on mortality in primary biliary cirrhosis: results of a 9year follow-up","volume":"53","author":"Jones","year":"2010","journal-title":"J\u00a0Hepatol"},{"issue":"5","key":"10.1016\/j.soc.2019.08.007_bib30","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/0016-5085(89)91698-3","article-title":"Ursodeoxycholic acid in primary biliary cirrhosis: results of a controlled double-blind trial","volume":"97","author":"Leuschner","year":"1989","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.soc.2019.08.007_bib31","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1002\/hep.28017","article-title":"The UK-PBC risk scores: derivation and validation of a scoring system for long-term prediction of end-stage liver disease in primary biliary cholangitis","volume":"63","author":"Carbone","year":"2016","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.soc.2019.08.007_bib32","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1111\/apt.13927","article-title":"The risk predictive values of UK-PBC and GLOBE scoring system in Chinese patients with primary biliary cholangitis: the additional effect of anti-gp210","volume":"45","author":"Yang","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.soc.2019.08.007_bib33","unstructured":"Carbone M, Nardi A, Carpino G, et al. Pre-treatment risk stratification in primary biliary cholangitis: A predictive model to guide first-line combination therapy. 50(1):21\u20132."},{"issue":"1","key":"10.1016\/j.soc.2019.08.007_bib34","first-page":"S355","article-title":"The novel hexokinase 1 antibodies are useful for the diagnosis and associated with bad prognosis in primary biliary cholangitis","volume":"66","author":"Reig","year":"2017","journal-title":"J\u00a0Hepatol"},{"issue":"6","key":"10.1016\/j.soc.2019.08.007_bib35","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1002\/hep.24283","article-title":"Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease","volume":"53","author":"Sookoian","year":"2011","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.soc.2019.08.007_bib36","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1053\/j.gastro.2013.03.051","article-title":"A\u00a0hepatocellular carcinoma 5-gene score associated with survival of patients after liver resection","volume":"145","author":"Nault","year":"2013","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.soc.2019.08.007_bib37","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1038\/s41598-017-00944-9","article-title":"Serum metabolomics analysis reveals a distinct metabolic profile of patients with primary biliary cholangitis","volume":"7","author":"Hao","year":"2017","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.soc.2019.08.007_bib38","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1111\/liv.12680","article-title":"Serum metabolic signatures of primary biliary cirrhosis and primary sclerosing cholangitis","volume":"35","author":"Bell","year":"2015","journal-title":"Liver Int"}],"container-title":["Surgical Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1055320719300791?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1055320719300791?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T12:04:04Z","timestamp":1760961844000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1055320719300791"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["S1055320719300791"],"URL":"https:\/\/doi.org\/10.1016\/j.soc.2019.08.007","relation":{},"ISSN":["1055-3207"],"issn-type":[{"type":"print","value":"1055-3207"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Individualizing Care","name":"articletitle","label":"Article Title"},{"value":"Surgical Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.soc.2019.08.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}